Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amgen’s Amjevita US Sales On The Rise, Oncology Biosimilars Still In Slump

Amgen Reported 36% Annual Global Sales Increase For Adalimumab Biosimilar After US Launch

Executive Summary

It seems that the first US Humira biosimilar is recovering from the predicted slow uptake, but Amgen’s oncology biosimilars portfolio continues to deteriorate.

You may also be interested in...



Amgen Forecasts ‘High Teens’ Growth For Biosimilars

Amgen expects future growth in the “high teens” for biosimilars, chairman and CEO Bob Bradway told the J.P. Morgan Healthcare Conference this week, also setting out his aspirations for the firm’s biosimilars pipeline.

Amgen Reveals First Figures For US Humira Rival

As Amgen and AbbVie reveal first-quarter results, a clearer picture is beginning to emerge of the dynamics for biosimilar competition to Humira in the US. But Amgen is cautioning that Q2 sales of Amjevita may not match initial uptake in Q1.

Amgen Builds Up Future Launches As Oncology Biosimilars Slide

Amgen’s biosimilars sales are on the decline, largely due to erosion of its oncology portfolio. However, the debut of first US Humira rival Amjevita, along with planned versions of Stelara and Eylea, are expected to push the segment back into growth.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153281

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel